Endoscopic Biliary Drainage in Malignant High Grade Biliary Stricture

Sponsor
Prince of Songkla University (Other)
Overall Status
Terminated
CT.gov ID
NCT03530527
Collaborator
(none)
10
2
2
15.8
5
0.3

Study Details

Study Description

Brief Summary

Biliary drainage is the mainstay of the palliative treatment in patients with inoperable malignant bile duct stricture. Endoscopic retrograde cholangiopancreatography (ERCP) is the cornerstone of biliary drainage method in these patients. However, ERCP is sometime unsuccessful to perform because of the presence of the high grade biliary stricture, tumor invasion of duodenum and ampulla of vater and surgically altered gastrointestinal anatomy. Endoscopic ultrasound (EUS) guided biliary drainage has been emerged as an alternative procedure to traditional surgical bypass and percutaneous trans hepatic biliary drainage after failed ERCP. There were few data to directly compare between ERCP and EUS guided biliary drainage and in patients with malignant high grade biliary stricture.

Condition or Disease Intervention/Treatment Phase
  • Procedure: ERCP with biliary stenting
  • Procedure: EUS guided biliary drainage
N/A

Detailed Description

The aim of this study is comparing the efficacy and complications between ERCP and EUS guided biliary drainage in patients with malignant high grade biliary stricture. Malignant high grade biliary stricture has not been well defined. The investigators define this malignant high grade biliary stricture using these arbitrary number include total bilirubin ≥ 15 mg/dl and or bile duct diameter ≥12 mm. based on the investigation's experience.

The study will be divided patients with inoperable malignant high grade biliary stricture into 2 groups, group (A) will be undergone ERCP with biliary stenting and group (B) will be undergone EUS guided biliary drainage. If the assigned intervention is not successful, then patients will be crossed-over to the another intervention.

Study Design

Study Type:
Interventional
Actual Enrollment :
10 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Endoscopic Retrograde Cholangiopancreatography Versus Endoscopic Ultrasound Guided Biliary Drainage in Inoperable Malignant Distal Bile Duct Obstruction
Actual Study Start Date :
Aug 20, 2018
Actual Primary Completion Date :
Nov 28, 2018
Actual Study Completion Date :
Dec 15, 2019

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: ERCP with biliary stenting

Patient will be undergone ERCP with biliary stenting for biliary decompression to relieve biliary obstruction.

Procedure: ERCP with biliary stenting
ERCP with biliary stent is performed using a side view duodenoscope of Olympus (TJF-160). Biliary cannulation is performed using a sphincterotome and 0.035 inch jag wire, and cholangiogarm is done to assess common bile duct diameter, and length of biliary stricture. Biliary sphincterotomy is then performed. A straight biliary stent is placed across stricture bile duct.
Other Names:
  • G1
  • Active Comparator: EUS guided biliary drainage

    Patient will be undergone EGBD for biliary decompression to relieve biliary obstruction.

    Procedure: EUS guided biliary drainage
    EUS guided biliary drainage is performed using a linear echoendoscope of Olympus (GFUCT240). Extrahepatic bile duct was identified from duodenal bulb, then 19 G needle is inserted into bile duct with confirmed with cholangiogram. The fistula tract is dilated using a 6 Fr cystotome (Wilson Cook Medical). A double pigtail stent is placed across biliary-enteric fistula.
    Other Names:
  • G2
  • Outcome Measures

    Primary Outcome Measures

    1. Technical success rate [24 hours]

      The number of patients with success of placement of stent in the desired. location

    Secondary Outcome Measures

    1. Clinical success rates [2 weeks]

      The number of patients with total bilirubin drop more than 30 % compare with baseline after successful biliary stent placement.

    2. Total procedure time [24 hours]

      The time interval between the intubation of the scope until the placement of the stent

    3. The complication rates [4 weeks]

      The number of patients who developed complications related procedure included pancreatitis, bleeding, perforation, cholangitis as defined and graded according to the consensus guideline.

    4. The mortality rates [1 weeks]

      The number of patients with death related to the procedure.

    5. Stent patency [12 weeks]

      The time interval between biliary stent insertion and the need for unscheduled re-interventions.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No

    Inclusion Criteria: I) Patients aged > 18 years. II) Clinical, laboratory data, imaging and or histology suggestive of malignant distal bile duct strictures that occurs as a result of pancreatic adenocarcinoma, cholangiocarcinoma, ampullary carcinoma, duodenal carcinoma, gallbladder cancer and metastasis malignant bile duct obstruction III) Inoperability by tumor staging, medically unfit or patient wishes

    1. distant metastasis

    2. major vascular involvement (unreconstructible Superior mesenteric vein/Portal vein, superior mesenteric artery, common hepatic artery and celiac artery)

    3. metastasis to lymphnode beyond the field or surgery IV) Jaundice, total bilirubin ≥15 mg/dl and/ or Common bile duct diameter ≥12 mm

    Exclusion Criteria: I) pregnancy II) uncorrectable coagulopathy ( international normalized ratio ≥ 1.5 ) III) thrombocytopenia (platelet count < 50,000 ) IV) extremely poor general condition, ERCP with stent insertion impossible for ethical reasons V) an extension of stricture to the main biliary confluent (hilum) or the existence of obstructive duodenal invasion VI) active suppurative cholangitis VI) surgically altered anatomy (i.e. Billroth II or Roux-en-Y reconstruction ) VII ) previous treatment with bile duct stent.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Prince of Songkla University Hat Yai Songkhla Thailand 90230
    2 NKC Institue of Gastroenterology and Hepatology, Prince of Songkla University Hat Yai Songkla Thailand 90110

    Sponsors and Collaborators

    • Prince of Songkla University

    Investigators

    • Principal Investigator: Nisa Netinatsunton, MD., NKC Institute of Gastroenterology and Hepatology, Faculty of Medicine, Prince of Songkla University, Hatyai, Songkhla, Thailand, 90110.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Nisa Netinatsunton, Secretory of NKC Institute of Gastroenterology and Hepatology, Prince of Songkla University
    ClinicalTrials.gov Identifier:
    NCT03530527
    Other Study ID Numbers:
    • REC 60-277-21-1
    First Posted:
    May 21, 2018
    Last Update Posted:
    Apr 1, 2021
    Last Verified:
    Mar 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Nisa Netinatsunton, Secretory of NKC Institute of Gastroenterology and Hepatology, Prince of Songkla University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 1, 2021